MDCO Gets 2nd Shot At Angiomax Patent Extension

Law360, New York (March 17, 2010, 4:17 PM EDT) -- The Medicines Co. has prevailed in its attempt to have the U.S. Patent and Trademark Office reconsider extending a patent for blood-thinning drug Angiomax.

There is no dispute that MDCO satisfied all of the substantive requirements necessary for an extension, Judge Claude M. Hilton of the U.S. District Court for the Eastern District of Virginia ruled Tuesday.

Judge Hilton set aside the USPTO’s decision to deny MDCO a patent extension and remanded the matter to allow the agency to reconsider the case “free from its erroneous...
To view the full article, register now.